These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23300275)

  • 1. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.
    Hoffman-Censits J; Kelly WK
    Clin Cancer Res; 2013 Mar; 19(6):1335-9. PubMed ID: 23300275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Asian J Androl; 2014; 16(6):803-4. PubMed ID: 25080931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide for the treatment of prostate cancer.
    Pal SK; Stein CA; Sartor O
    Expert Opin Pharmacother; 2013 Apr; 14(5):679-85. PubMed ID: 23441761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all.
    Maughan BL; Antonarakis ES
    Asian J Androl; 2014; 16(6):807-8. PubMed ID: 25155108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance.
    Lochrin SE; Figg WD; Finn SP
    Cancer Biol Ther; 2015; 16(2):201-3. PubMed ID: 25569176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
    Ho AL; Foster NR; Zoroufy AJ; Campbell JD; Worden F; Price K; Adkins D; Bowles DW; Kang H; Burtness B; Sherman E; Morton R; Morris LGT; Nadeem Z; Katabi N; Munster P; Schwartz GK
    J Clin Oncol; 2022 Dec; 40(36):4240-4249. PubMed ID: 35867947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday.
    Kawahara T; Miyoshi Y; Yao M; Uemura H
    Case Rep Oncol; 2019; 12(2):568-572. PubMed ID: 31427954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia.
    Kawahara T; Miyoshi Y; Yao M; Uemura H
    Case Rep Oncol; 2019; 12(2):589-594. PubMed ID: 31543773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer.
    Thompson TC; Li L
    Mol Cell Oncol; 2017; 4(4):e1321167. PubMed ID: 28819638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
    N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide in European and North American men participating in the AFFIRM trial.
    Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
    BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
    Bennett LL; Ingason A
    Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
    Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
    Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
    Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
    Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
    Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
    Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
    Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Hirmand M; Smith MR
    Lancet Oncol; 2014 May; 15(6):592-600. PubMed ID: 24739897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
    Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D;
    Prostate; 2015 Jun; 75(8):836-44. PubMed ID: 25683285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on enzalutamide in the treatment of prostate cancer.
    Merseburger AS; Haas GP; von Klot CA
    Ther Adv Urol; 2015 Feb; 7(1):9-21. PubMed ID: 25642291
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.